A new study released Monday said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally ...

Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations in mild or moderate COVID-19 in a phase 3 ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

Merck (MRK) said Monday it has submitted a formal application to the Food & Drug Administration for emergency approval of its oral COVID treatment. Merck said it's seeking Emergency Use ...

The FDA authorized Merck’s drug for adults with a positive COVID-19 test, early symptoms and who face the highest risks of hospitalization, including older people and those with conditions like ...

Drug companies have enlisted generic manufacturers before with $4 and $4, typically after public pressure. For its COVID-19 pill, Merck has set up these partnerships ahead of time, preemptively ...

An experimental COVID-19 treatment pill called Molnupiravir ... pill said to be effective against the virus. The drug manufacturer- Merck’s clinical trial on the pill Molnupiravir has been ...

WASHINGTON - A panel of U.S. health advisers on Tuesday narrowly backed a closely watched COVID-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans ...

Phase 3 trials show that Merck's oral pill Molnupiravir is highly ... 2-DG is a safe and effective COVID-19 drug, but not meant for people with underlying health problems, says DRDO in its ...

Japan has entered negotiations with U.S. pharmaceutical company Merck & Co. for special approval and procurement this year of its oral antiviral drug for COVID-19 patients. Merck has conducted ...

The US Food and Drug Administration recently authorised Merck's Molnupiravir for treatment of mild-to-moderate COVID-19 cases in adults who are at risk for severe disease. Before that in November ...